Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

CKD Stage 3

Tundra lists 4 CKD Stage 3 clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07494045

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency. The main questions it aims to answer are: 1. To assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 Capsules 2. To investigate the safety and tolerability of CTAP101 Capsules Participants will take a daily dosage of CTAP101 Capsules at bedtime for 8 weeks.

Gender: All

Ages: 1 Month - 17 Years

Updated: 2026-03-30

5 states

CKD Stage 3
CKD Stage 4
Secondary Hyperparathyroidism
+1
NOT YET RECRUITING

NCT07483697

Multimodal Intervention for Early Chronic Kidney Disease in Young People: Dysbiosis and Inflammation (CKD)

Chronic kidney disease (CKD) is a progressive condition associated with substantial morbidity, mortality, and healthcare costs. Early detection and timely intervention are critical to modify disease trajectory, particularly in adolescents and young adults. Emerging evidence supports the role of the gut-kidney axis in CKD progression, whereby intestinal dysbiosis contributes to systemic inflammation and accumulation of microbiota-derived uremic toxins. This randomized controlled clinical trial aims to evaluate whether a multimodal intervention consisting of a controlled diet, structured exercise, and a symbiotic administered for 180 days improves uremic toxin burden, systemic inflammation, and early renal outcomes compared with standard care plus placebo.

Gender: All

Ages: 14 Years - 35 Years

Updated: 2026-03-19

1 state

Exercise
Diet Interventions
Symbiotic
+3
RECRUITING

NCT06360380

Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System

The REFORM-HF study aims to test a new technology, AquaPass, designed to assist patients experiencing symptoms of fluid overload due to Heart Failure. Patients will wear a lightweight suit that helps remove excess fluids through their sweat. The investigators want to see if the AquaPass system can remove an additional 500mL of fluids during treatment, alongside patients' regular medications like diuretics. Participants will select if to be treated at their home or in the outpatient clinic.

Gender: All

Ages: 21 Years - 80 Years

Updated: 2024-09-19

2 states

Chronic Heart Failure
CKD Stage 3
ENROLLING BY INVITATION

NCT05514184

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

In this pilot clinical trial, the investigators will recruit and randomize 120 patients with diabetes mellitus and chronic kidney disease (CKD/DM) stages 3 to 5 to a patient-centered and flexible Plant-Focused Nutrition in Diabetes (PLAFOND) diet with \>2/3 plant-based sources, which will be compared with a standard-of-care CKD diet, which is usually a low-potassium and low-salt diet, over a 6-month period. Through this study, the investigators will determine whether the plant-focused diet intervention is feasible for patient adherence, whether this diet is safe by avoiding malnutrition, frailty, and high potassium or glucose blood levels, and whether patient reported outcomes are favorably impacted.

Gender: All

Ages: 18 Years - Any

Updated: 2024-07-03

1 state

Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM)
CKD Stage 3
CKD Stage 4
+3